The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor.

What Was Tested

This clinical trial looks at Chorionic Gonadotropin.

To evaluate systemic and ovarian changes in levels of interleukin (IL)-1beta, IL-6, and vascular endothelial growth factor (VEGF) in response to hCG administration to determine which may be the potential initiator of vascular effects and to identify the main source of the substance; to evaluate serum and follicular fluid levels of these cytokines as markers of ovarian hyperstimulation syndrome (OHSS), and to compare levels of these cytokines under basal conditions in women with normal ovulation and those with polycystic ovary syndrome (PCOS).

Women undergoing IVF, in whom the first two study objectives were analyzed, and women with normal ovulation and patients with PCOS undergoing retrieval of immature oocytes in natural cycles or cycles stimulated for IUI but cancelled during induction of ovulation, in whom the third study objective was analyzed.

Who Took Part

PubMed tags the participants as women only.

How the Study Was Run

In vitro fertilization program at the Instituto Valenciano de Infertilidad, Valencia, Spain.

Serum was collected before and after hCG administration, and follicular fluid was collected at ovum pick-up.

What Was Measured

The subject headings attached to it are Chorionic Gonadotropin, Endothelial Growth Factors, Fertilization in Vitro, Follicular Fluid, Interleukin-1, Interleukin-6 and Lymphokines.

What This Means in Plain Language

This is a clinical trial of Chorionic Gonadotropin.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (Fertility and sterility), a journal based in United States.

More context: the related hCG (human chorionic gonadotropin) library page, all human trials.